Axial Therapeutics
Woburn · Biotechnology, Healthcare, Health Care · 12 employees
Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases. The company is the scientific leader in the biological role of the microbiome gut-brain axis and its influence on the central nervous system. Harnessing its unique expertise in the microbiome, Axial is developing small molecule drugs with defined mechanisms of act
Funding history
- Funding Round — $19.4M — Feb 2025
- Funding Round — $27.4M — Oct 2023
- Funding Round — $27.4M — Oct 2021
- Series series c — $37.3M — Oct 2021
- Series seed — $4.8M — May 2021
Recent signals
- Feb 11, 2025: Raised $19.4M
- Oct 27, 2023: Raised $27.4M
- Oct 25, 2021: Raised $27.4M
- Oct 13, 2021: Raised $37.3M in Series series c
- May 26, 2021: Raised $4.8M in Series seed
- May 22, 2020: Raised $7.8M
- Jun 24, 2019: Raised $5.0M
- Nov 21, 2018: Raised $20.0M
See plans & pricing → Track Axial Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.